Hanna Ng, Director, Preclinical Safety, Preclinical Development

Toggle Menu

Hanna Ng

Director, Preclinical Safety, Preclinical Development

Hanna Ng, Ph.D., D.A.B.T., has significant experience managing large National Institutes of Health (NIH) funded programs. She currently serves as the Principal Investigator (PI) for the NHLBI SMARTT program’s pharmacology and toxicology center and the toxicology and pharmacokinetics programs for NIMH. Ng is also the associate PI for the NIAID program to conduct toxicity and PK studies of anti-infective therapeutics. 

Ng has over twelve years experience conducting preclinical studies for a wide range of therapeutic uses and molecular structures, including biologics, small molecules, vaccines, monoclonal antibodies, imaging agents, and combination drug therapies.  She served on the technical evaluation panel for the NCI Pediatric Preclinical Testing Program and the NCI SBIR Phase I and Phase II for several research topics.  She also has specialized expertise in toxicogenomics, and published seminal work on the host response of animals to bacterial infections.

Prior to joining SRI, Ng was a postdoctoral fellow in the Department of Medicine at the University of California, Los Angeles. Ng received a B.S. in biology from Beijing Normal University, M.A. in molecular biology from Clark University, and a Ph.D. in toxicology/environmental health sciences from Johns Hopkins University.  She has been a board certified toxicologist since 2004.

Hanna Ng